High Ki-67 Immunohistochemical Reactivity Correlates With Poor Prognosis in Bladder Carcinoma

Luo, Yihuan; Zhang, Daniel Xin; Mo, Meile; Tan, Zhihong; Huang, Lanshan; Zhou, Hong; Wang, Chunqin; Wei, Fanglin; Qiu, Xiaohui; He, Rong‐Quan; Chen, Gang

doi:10.1097/md.0000000000003337

Cited by 24 publications

(18 citation statements)

References 120 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In China, BLCA was the thirteenth most common cancer with a total number of 80, 500 cases in 2015 [3]. The mechanisms of BLCA however remain largely unclear, which has led to the paucity of specific biomarkers for screening, surveillance, or prognostic stratification of BLCA [4][5][6][7][8][9][10]. Hence, there is an urgent need to identify new reliable biomarkers related to prognosis.…”

Section: Introductionmentioning

confidence: 99%

RNA-Sequencing Data Reveal a Prognostic Four-lncRNA-Based Risk Score for Bladder Urothelial Carcinoma: An in Silico Update

Huang²,

et al. 2018

Cell Physiol Biochem

Self Cite

View full text Add to dashboard Cite

Background/Aims: Current practical advances in high-throughput data technologies including RNA-sequencing have led to the identification of long non-coding RNAs (lncRNAs) for potential clinical application against bladder urothelial cancer (BLCA). However, most previous studies focused on the clinical value of individual lncRNAs, which has limited the potential for future clinical application. Methods: In this study, RNA-sequencing data of lncRNAs was downloaded from The Cancer Genome Atlas database. Risk score was constructed based on survival-associated lncRNAs identified using differential expression analysis as well as univariate and multivariate Cox proportional hazards regression analysis. Receiver operating characteristic and Kaplan-Meier curve analyses were employed to evaluate the clinical and prognostic value of risk scores. Bioinformatics analyses were used to investigate the potential mechanisms of newly identified lncRNAs. Results: Among 2,127 differentially expressed lncRNAs (DELs), four new lncRNAs (AC145124.1, AC010168.2, MIR200CHG, and AC098613.1) showed valuable prognostic effects in BLCA patients. More importantly, the four-DEL-based risk score had the potential to become an independent marker for the survival status prediction of BLCA patients. Distinct co-expressed genes and signaling pathways were identified when BLCA was categorized into low- and high-risk groups. Furthermore, a protein-coding gene, HIST4H4 was found only 68 bp from the AC010168.2 DEL. HIST4H4 expression level was evidently up-regulated and positively correlated with AC010168.2 in BLCA patients. Conclusion: This in silico investigation pioneers the future investigation of the utility of prognostic lncRNAs for BLCA.

show abstract

Section: Introductionmentioning

confidence: 99%

RNA-Sequencing Data Reveal a Prognostic Four-lncRNA-Based Risk Score for Bladder Urothelial Carcinoma: An in Silico Update

Huang²,

et al. 2018

Cell Physiol Biochem

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…The Ki-67 protein is an (IHC) marker of cell proliferation associated nuclear antigen which is expressed in dividing cells during cell cycle (G1, S, G2 and M) but not on (G0) [6,7]. The labeling index of Ki-67 has a direct correlation with the degree of cells proliferation, and has prognostic value in several types of cancer [8][9][10][11][12]. The Ki-67 is a commonly used proliferation marker in breast cancer.…”

Section: Introductionmentioning

confidence: 99%

“…Tumor cells proliferation is an important biological parameter that reflects disease behavior, which might also predicts for disease prognosis. The nuclear protein Ki-67 is a proliferative marker and widely used prognostic indicator in several cancer diagnosis, including breast cancer, bladder cancer, gastrointestinal neuroendocrine tumor, oral cancer, lung cancer, astrocytoma, and pituitary adenoma [8][9][10][11][12]23,24].In endometrial cancers, Ki-67 in addition to other biomarkers was found to be useful marker to distinguish benign proliferative conditions from cancer precursors and low grade endometrioid adenocarcinomas (16,25). In a study on 270 endometrial samples Ki-67 expression was found to be higher in samples with high-grade endometrioid carcinomas vs normal endometrial samples [26].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Can Ki-67 Predict Pelvic Node Status in Endometrial Adenocarcinoma?

2016

J Cancer Sci

View full text Add to dashboard Cite

Background: The Ki-67 marker is a nuclear protein that has a direct correlation with the degree of cells proliferation that often expressed in human neoplasm.Objective: To evaluate utilization of Ki-67 expression as predictor for pathological nodal positivity in endometrial endometrioid adenocarcinoma.Design: A retrospective case control study. Settings: Tertiary cancer center. Materials and methods:We evaluated 12 histopathological slides for patients with endometrioid adenocarcinoma of the uterus for percentage of expression of Ki-67. We defined high expression as Ki-67 stained > 50% of tumor cells. Main outcome measures:The correlation of Ki-67 high expression rates and pelvic node positivity in endometrioid adenocarcinoma.Results: Our sample mean age at diagnosis is (58.25 years) and median age is (57 years). The rate of high expression of Ki-67 in tumor cells among cases with positive lymph nodes vs controls were significantly higher (83%) vs (17%), with (p-value = 0.04). There were no significant differences between the mean age in cases and controls (59.8 vs 56.67) with (p = 0.67), tumor grade (p = 0.3), myometrium invasion (p = 0.1), cervical stromal invasion (p = 0.2), lymphovascular invasion (p = 0.2). On multivariate analysis a high expression of Ki-67 continued to be independent predictor for lymph node positivity (p = 0.02). Conclusions:This finding suggests that a high expression of Ki-67 plays an important role as predictor for lymph node positive in endometrioid adenocarcinoma. The level of expression of Ki-67 can be utilized for preoperative or postoperative risk assessment to predict for lymph node metastasis for cases with borderline indications for postoperative pelvic irradiation. Further prospective larger study is needed to validate this preliminary data. Page -02 ISSN: 2377-9292 adenocarcinoma of the uterus. The study was conducted in tertiary cancer center at King Abdullah Medical City. The protocol was reviewed and approved by institutional review board. Population was identified via search of hospital Electronic Medical Records between June of 2014 and June of 2016. We identified 48 cases with endometrial adenocarcinoma, then we identified 6 cases with pelvic node positive disease with no distance metastasis and we identified 6 matched controls of node negative. We match the cases and control for age and other clinicopathological characteristics including: tumor grade, lymphovascular space invasion, myometrial invasion and cervix invasion. The Immunohistochemical stain of Ki-67 was carried on unstained pathological slides taken from formalin-fixed, paraffinembedded tissues by standard automated immunohistochemistry on Ventana machine.We defined high expression as Ki-67 staining > 50% of tumor cells. All readings of the percentage of Ki-67 were carried out by one pathologist to overcome observers' variation (Figures 1 and 2). Statistical analysisCollected data was transferred and analyzed by using SPSS ver. 24 (SPSS Inc.). The correlation of high expression of Ki-67 with pelv...

show abstract

“…Согласно результатам мультивариантного анализа, повы шенный Ki-67 был достоверно ассоциирован с плохим прогнозом среди всех популяций: HR 1,868 (95% CI 1,343-2,597, р < 0,001) для опухолеспецифической выживаемости (CSS), HR 2,626 (95% CI 2,089-3,301, р < 0,001) для выживаемости без заболевания (DFS), HR 1,104 (95% CI 1,008-1,209, р = 0,032) для общей выживаемости (OS), HR 1,518 (95% CI 1,299-1,773, р < 0,001) для выживаемости без прогрессии (PFS) и HR 1,294 (95% CI 1,203-1,392, р < 0,001) для выживаемости без рецидива (RFS). Эти результаты позволяют сделать вывод о том, что Ki-67 может рассматриваться в качестве независимого прогностического маркера при РМП [26].…”

unclassified

Clinical, morphological and molecular genetic prognostic factors for survival rates in non-muscle-invasive bladder cancer

Каприн¹,

Аполихин²,

Alekseev³

et al. 2018

Onkol. Z. im. P.A. Gercena

View full text Add to dashboard Cite

Рак мочевого пузыря (РМП)-один из наиболее часто встречающихся видов злокачественных опухолей мочеполовой системы у взрослых. В мире заболеваемость РМП составляет более 450 тыс. новых случаев ежегодно [1]. Признанным стандартом первого этапа лечения является лечебно-диагностическая трансуретральная резекция новообразования с подлежащими структурами, обязательно включающими мышечный слой стенки мочевого пузыря. Мышечно-неинвазивный рак мочевого пузыря (МНРМП) является гетерогенной патологией, включаю-щей в себя несколько различных форм с независимыми патологическими механизмами развития и, соответственно, разным вероятным исходом. Несмотря на сходные клинико-морфологические характеристики опухоли, течение опухолевого процесса у разных пациентов может различаться. Для уточнения клинической эффективности существующих лечебных подходов в практику введены стан

show abstract

High Ki-67 Immunohistochemical Reactivity Correlates With Poor Prognosis in Bladder Carcinoma

Cited by 24 publications

References 120 publications

RNA-Sequencing Data Reveal a Prognostic Four-lncRNA-Based Risk Score for Bladder Urothelial Carcinoma: An in Silico Update

RNA-Sequencing Data Reveal a Prognostic Four-lncRNA-Based Risk Score for Bladder Urothelial Carcinoma: An in Silico Update

Can Ki-67 Predict Pelvic Node Status in Endometrial Adenocarcinoma?

Clinical, morphological and molecular genetic prognostic factors for survival rates in non-muscle-invasive bladder cancer

Contact Info

Product

Resources

About